Abstract:BACKGROUND: Metastatic non-small cell lung cancer (NSCLC) has many comorbidities, such as chronic obstructive pulmonary disease, coronary heart disease, and older age-related comorbidities. A survival benefit was observed in such patients who underwent surgery for selected oligometastatic disease. However, to the best of our knowledge, there is no evidence to support whether lobectomy (compared with sub-lobar resection) would further prolong these patients' lives.METHODS: Patients with metastatic NSCLC who underwent primary tumor resection were identified from the Surveillance, Epidemiology, and End Results (SEER) database and then divided into lobectomy and sub-lobar resection groups. Propensity score matching (PSM, 1:1) was performed to match the baseline characteristics of the two groups. Cancer-specific survival (CSS) was estimated.RESULTS: In total, 24,268 patients with metastatic NSCLC were identified; 4,114 (16.95%) underwent primary tumor surgery, and of these, 2,045 (49.71%) underwent lobectomy and 1,766 (42.93%) underwent sub-lobar resection. After PSM, 644 patients in each group were included. Lobectomy was independently correlated with longer median CSS time [hazards ratio (HR): 0.70, 95% confidence interval (CI): 0.61-0.80, P<0.001]. The 1, 2, and 3-year survival rates after PSM also favored the lobectomy group. However, no significant survival difference was found for wedge resection and segmentectomy (HR: 0.96, 95% CI: 0.70-1.31, P=0.490). The 1-, 2-, and 3-year survival rates after PSM also exhibited no difference within the sub-lobar group. We explored whether lymph node dissection would provide additional survival benefits for stage IV NSCLC patients. According to the multivariate Cox analysis of the matched population, lymph node dissection was independently associated with better CSS (HR: 0.76, 95% CI: 0.66-0.88, P<0.001) and overall survival (OS) (HR: 0.74, 95% CI: 0.65-0.86, P<0.001). We confirmed this result in the different types of surgery and found that the lymph node dissection group consistently had better survival outcomes both in the lobectomy group and sub-lobar resection population. According to the subgroup analysis, with the exception of stage T4 and brain metastatic patients, all of the patient subtypes exhibited greater benefit from lobectomy than sub-lobar resection.CONCLUSIONS: Lobectomy has a greater survival benefit in metastatic NSCLC patients compared with sub-lobar resection when radical treatment of primary site was indicated.

[Current Situation and Confusion of Sublobar Resection for Early Stage Lung Cancer].

Sublobar Resection Is Associated With Better Perioperative Outcomes In Elderly Patients With Clinical Stage I Non-Small Cell Lung Cancer: A Multicenter Retrospective Cohort Study

Effectiveness and Safety of Systematic and Selective Lymphadenectomies in Chinese Patients with Non-Small Cell Lung Cancer Who Received Sublobar Resection.

Sublobar or Lobar Resection in Early-Stage Peripheral Non-Small Cell Lung Cancer Less Than 2cm: a Meta-Analysis for Randomized Controlled Trials

Sublobar Resection vs Lobectomy for Stage IA Non-Small Cell Lung Carcinoma—Takeaways From Modern Randomized Trials

[Issues Need to Be Considered in Sublobectomy for Early Stage Lung Cancer].

Sublobar Resection vs Lobectomy for High-Risk Stage I Non–Small Cell Lung Carcinoma

Sublobar Resection for Lung Adenocarcinoma Less Than 2 Cm Containing Solid or Micropapillary Components Radiologically Presented As Consolidation-to-tumor Ratio (CTR) ≤0.25 [Ground-Glass Opacity (GGO)]

Prognostic Impact of Lymphadenectomy on Outcomes of Sublobar Resection for Stage IA Non–small Cell Lung Cancer ≤2 Cm

Lobar or sublobar resection of peripheral stage I non-small cell lung cancer

Sublobectomy Versus Lobectomy for Long-Term Survival Outcomes of Early-Stage Non-Small Cell Lung Cancer with a Tumor Size ≤2 Cm Accompanied by Visceral Pleural Invasion: a SEER Population-Based Study

Sublobar Resection for Pulmonary Aspergilloma: A Safe Alternative to Lobectomy

Surgery for advanced-stage non-small cell lung cancer: lobectomy or sub-lobar resection?

Effectiveness And Safety Of Lobectomy And Sublobar Dissection In Chinese Elderly Patients With Non-Small Cell Lung Cancer: A Real-World Observational Study.

Sublobar resection in early non-small cell lung cancer with epidermal growth factor receptor mutant

Sublobar Resections for Small-Sized Stage Ia Lung Adenocarcinoma: a Sino-Japanese Multicenter Study

Sublobar resection versus lobectomy in Surgical Treatment of Elderly Patients with early-stage non-small cell lung cancer (STEPS): study protocol for a randomized controlled trial

Long term outcomes after lobar versus sublobar resection for patients with Non-Small cell lung Cancer: Systematic review and individual patient data Meta-Analysis

Sublobar Resection Versus Lobectomy in Patients Aged ≤35 Years with Stage IA Non-Small Cell Lung Cancer: a SEER Database Analysis.

Oncological Outcomes of Sub-Lobar Resection Versus Lobectomy for Stage I Non-Small Cell Lung Cancer

Lymphadenectomy for clinical early-stage non-small-cell lung cancer: a systematic review and meta-analysis.